371 results about "Neoplastic disease" patented technology

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a hydroxyl-substituted dihydroisoquinolinone compound. The compound has a good KRAS G12V mutant gene inhibition effect, and can be used for treating tumor diseases related to KRAS G12V gene mutation.

A method based on a multi-task learning model comprises the following steps: acquiring and processing histopathological image data of gastritis through a data preparation and preprocessing step; feature extraction is performed by using a self-supervised learning pre-trained model, and image blocks are coded into high-dimensional feature vectors; and constructing a multi-task learning model, learning feature representation through a full connection layer module and an attention layer module, and outputting a classification result of each task. And carrying out model training and optimization by using an optimizer, adding multitask loss through a loss function, and dynamically adjusting the model performance. The trained model can automatically detect and grade gastritis, atrophy, acute activity, intestinal metaplasia and other pathological indexes, outputs a standardized evaluation result, and assists in pathological diagnosis. According to the method, a multi-task deep learning framework based on self-supervised learning pre-training is constructed, a traditional single-task modeling mode is broken through, deep learning framework design is driven through pathological index association, and accuracy and clinical practicability of non-neoplastic disease assessment of the stomach are remarkably improved.

Provided in the present invention are compounds shown as formula (I) and racemates, stereoisomers, tautomers, nitrogen oxides, solvates, polymorphs, metabolites, esters, prodrugs or pharmaceutically acceptable salts thereof, which have good p53-Y220C mutant activation effect, can be used for treating tumor diseases containing p53-Y220C mutant proteins, and can be used for preparing drugs for such disorders or diseases.

The invention discloses a tumor disease assessment method based on big data, and particularly relates to the technical field of tumor disease assessment. Medical data and living habit data of a patient are collected through multiple data interfaces, integration is carried out through preprocessing and a multi-modal data fusion technology, tumor microenvironment features and drug metabolism features are extracted, a comprehensive feature vector is generated, the effectiveness of a chemotherapy regimen is predicted by using a machine learning model, and when the effectiveness of the chemotherapy regimen is low, the chemotherapy regimen is identified. Newest clinical tests and drug data are introduced regularly, model parameters are dynamically optimized in combination with the chemotherapy regimen improvement effect, it is ensured that the model reflects the newest clinical progress in real time, the problems of model updating lag and drug innovation mismatching are effectively solved, the accuracy and effectiveness of a treatment regimen are improved, and the treatment cost is reduced. And meanwhile, side effects caused by blind attempts are reduced, and powerful support is provided for personalized precise medical treatment.

The disclosure includes compounds of Formula (I)wherein Q1, Q2, Q3, W, X, Y, Z1, m, n, Warhead, R1, R2, R3, R4, and R5, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.

The present application discloses substituted polycyclic heterocycles compound of Formula (I), pharmaceutically acceptable salt and / or solvate and pharmaceutical compositions thereof useful in the treatment of proliferative disease or condition characterized by a dysregulation of the RAS-ERK pathway such as neoplasm disease or disorder, inflammatory disease or immune system disorder.

The present invention relates to the field of cancer therapy. In particular, the present invention relates to a first composition comprising a live attenuated bacterium for use in the treatment, prevention, reduction, inhibition, prevention of recurrence, or control of a neoplastic disease in a subject being or intended to be administered a second composition comprising a live attenuated bacterium, said bacterium being the same or different to that of the first composition and methods thereof.

The disclosure includes compounds of Formula (A), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

The invention relates to a sulfonyl compound and a pharmaceutical composition and application thereof. The sulfonamide compound comprises a compound as shown in formula I: # imgabs0 #. The sulfonamide compound has a benzyne structure located on the left side of sulfonyl and a pyridino isoxazole structure located on the right side of sulfonyl. Through the synergistic effect of sulfonyl, a benzyne structure and a pyridoisoxazole structure, the druggability of the compound and the capability of competitively combining with acetyl coenzyme to KAT6A / KAT6B can be remarkably improved, the acetyl coenzyme is inhibited from combining with KAT6A / KAT6B to catalyze histone related sites, and gene expression inducing cancer cell growth is prevented; further, the KAT6A / KAT6B gene can be used for treating related tumor diseases caused by KAT6A / KAT6B gene amplification or KAT6A / KAT6B protein overexpression.

The present invention relates to the ranking / selection of tumor-specific neoantigens of a subject having cancer. The present invention also provides methods using the ranked / selected tumor-specific neoantigens in. for example. the treatment or prevention of cancer. Ranked and selected neoantigens may be used as biomarkers in the diagnosis, monitoring and / or prognosis of tumor diseases.

The disclosure includes compounds of any one of Formulae (0)-(5), (11)-(24), (A)-(E), and (1)-(V) comprising an E3 ubiquitin ligase binding moiety that binds an E3 ubiquitin ligase, as described herein. Also disclosed pharmaceutical compositions comprising compounds, and a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.

The disclosure includes compounds of Formula (A):wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

The disclosure includes compounds of Formula (I)wherein W, R1, R2, R3, R4, R5, R6, m, n, L, and Z1, are defined herein. Also disclosed is a method for treating a neoplastic disease and autoimmune disease with these compounds.

The disclosure includes compounds of Formulae (1) wherein Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Qx, R1, R2, R3, R4, R5, R6, R7, R9, R10, R11, Rx, a, b, c, g, j, k, m, n, u, v, L, Z1, Z2, Z4, and Z5 are defined herein. Also disclosed is a method for treating a neoplastic disease and autoimmune disease with these compounds.

The disclosure includes compounds of Formula (A):wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

Described is an antibody-drug conjugate (ADC) having the formula A-L, wherein A is an antibody or an antibody fragment and wherein L is a linker, said linker comprising: as a first payload a topoisomerase I inhibitor which is cell-permeable, preferably a camptothecin cytotoxic molecule which is cell-permeable; and as a second payload a topoisomerase I inhibitor which is not cell-permeable, preferably a camptothecin cytotoxic molecule which is not cell-permeable. Moreover, described is a pharmaceutical composition comprising said ADC and at least one pharmaceutically acceptable ingredient. Further, described is an ADC for use in a method of treating a patient suffering from, being at risk of developing, and / or being diagnosed for a neoplastic disease.

The invention discloses application of a Lys35 site of a PC4 protein as a target spot in preparation of tumor diagnosis and treatment products. The invention provides application of a Lys35 site of a PC4 protein as a target spot in preparation of a tumor diagnosis product. The research shows that the Lys35 site methylation of the PC4 protein can promote the cell cycle progress of tumor cells and promote the proliferation growth and malignant progression of the tumor cells, and the scheme for inhibiting the site methylation can be used for developing tumor treatment drugs. Therefore, the Lys35 site of the PC4 protein can be used as a key target to be applied to development of tumor diagnosis products and targeted therapy drugs. The invention further develops the PC4 protein Lys35 methylation antigen peptide and the antibody capable of specifically recognizing the PC4 protein Lys35 methylation site, and the PC4 protein Lys35 methylation antigen peptide and the antibody can be applied to regulation and control of tumor cell proliferation or growth, can be used for developing diagnostic products and targeted therapy drugs for clinical tumor diseases, and have good clinical application value.

Compounds of formulae (I) and (II)which are novel inhibitors of human dihydroorotate dehydrogenase (hDHODH) and pharmaceutical compositions containing the compounds of formulae (I) and (II) are provided. A method for treating tumor diseases, including acute myelogenous leukemia (AML), triple-negative breast cancer, PTEN-mutant tumors, and KRAS-driven tumors by administering pharmaceutical compositions containing the compounds of formulae (I) and (II) is also provided.

The invention discloses a brain tumor disease treatment effect evaluation method, and belongs to the technical field of radiotherapy plan evaluation, and the method specifically comprises the steps: obtaining the brain multi-modal image data of a patient, and extracting a three-dimensional tumor region and a corresponding perfusion parameter; constructing a biological target region hierarchical structure containing a tumor overall region and an anoxic subregion; a relative hypoxia degree parameter is obtained by calculating the cerebral blood flow ratio of the hypoxia subregion to other regions of the tumor; historical treatment case data are deconstructed, and a dose-curative effect associated parameter set is established; training and outputting a dose adjustment strategy model for the hypoxia subregion; and generating a final radiotherapy dose planning scheme according to a dose adjustment value output by the model in combination with a clinical guide basic dose. Through a data-driven dose decision-making mechanism, the limitation of traditional uniform dose irradiation is overcome, so that an objective and reliable evaluation basis is provided for clinical selection and optimization of personalized treatment schemes.

The invention relates to a method for diagnosing a tumour disease in an isolated sample, comprising the amplification of methylated DNA sequences, to a kit for diagnosing a tumour disease, and to the use of the method and / or of the kit for the diagnosis and / or progress control of a malignant tumour disease, in particular of prostate, breast, ovarian or colorectal carcinomas. The invention furthermore relates to a computer program product comprising risk score analysis commands for diagnosing a tumour disease, and to a data processing device.

Described is an antibody-drug conjugate (ADC) having the formula A-L, wherein A is an antibody or an antibody fragment and wherein L is a linker, said linker comprising: as a first payload a topoisomerase I inhibitor which is cell-permeable, e.g., a camptothecin cytotoxic molecule which is cell-permeable; as a second payload a topoisomerase I inhibitor which is not cell-permeable, e..g., a camptothecin cytotoxic molecule which is not cell-permeable; and as a as a third payload a toxin or a cytotoxin, e.g., an auristatin such asMMAE (Monomethyl auristatin E). Moreover, described is a pharmaceutical composition comprising said ADC and at least one pharmaceutically acceptable ingredient. Further, described method of treating a patient suffering from, being at risk of developing, and / or being diagnosed for a neoplastic disease.

The invention discloses a quantum precision detection method for low-abundance miRNA (micro Ribonucleic Acid). According to the method, a miRNA sensing strategy is established through capture and enrichment of fluorescent nano-diamond by magnetic particles; the method comprises the following analysis steps: introducing an electric field to regulate and control the charge state population degree of a fluorescent nano-diamond NV color center, applying radio frequency microwaves to control the quantum spin state of the NV color center, and collecting and analyzing the fluorescence difference before and after electric field regulation and control and microwave control so as to accurately judge the intensity of a detection signal; according to the method, sensitive detection and accurate concentration quantification of low-abundance miRNA can be realized, and a detection means can be provided for finer division of tumor diseases in the early stage.

The present disclosure relates to bioactive conjugates and preparation methods and uses thereof, and specifically discloses a ligand-drug conjugate represented by formula XV, a preparation method thereof, and its use in preventing and / or treating diseases associated with abnormal cell activity, including but not limited to preventing and / or treating tumor diseases. #imgabs0#

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and / or melanoma and the like.

The invention relates to a multiple miRNA (micro Ribonucleic Acid) detection method based on deoxyribozyme or CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) / The detection method provided by the invention comprises the following steps: designing a probe 1 and a probe 2 matched with different targets according to the different targets; when a target exists, the probe 1 and the probe 2 are connected to miRNA through T4DNA liguase, then DNA polymerase is introduced for amplification of a DNA chain, the released miRNA is further hybridized with a new probe, the next round of reaction is activated, and signals are circularly amplified. The S1 duplex body generated after amplification can be subjected to multiple characterization through two design modes: the first mode is based on deoxyribozyme detection; and the second mode is to carry out detection based on CRISPR / Cas12a. The method provided by the invention can realize detection of multiple tumor miRNAs, is short in detection time, and provides an important theoretical basis for treatment of tumor diseases.

The present invention relates to the field of cancer therapy. In particular, the present invention relates to a live attenuated Gram-negative bacterium for use in the treatment, reduction, inhibition or control of a neoplastic disease in a subject undergoing or intended to undergo immunotherapy with a checkpoint inhibitor therapy, an adoptive T cell therapy and / or an allogeneic or an autologous CAR-T therapy simultaneously, separately or sequentially with the administration of the live attenuated Gram-negative bacterium.

The invention relates to the technical field of biological medicines, and particularly discloses a transcription factor HOMEZ phosphorylation site specific antibody as well as a preparation method and application thereof. The specific antibody provided by the invention can specifically recognize phosphorylation of the 451st site threonine of HOMEZ in a tumor specimen, so that the prognosis condition of the tumor is judged, and a potential action target is provided for clinical diagnosis and treatment of the tumor; moreover, the specific antibody disclosed by the invention can be used for detecting the expression difference between normal cells and tumor cells in a Western blot experiment, and is beneficial to research on the effect of phosphorylation modification of HOMEZ protein in the occurrence and development process of tumor diseases; and the kit can also be used for detecting the phosphorylation level of the HOMEZ protein in a clinical specimen through experiments such as immunofluorescence and immunohistochemical staining, and has a wide clinical application prospect in the aspects of disease diagnosis, treatment, prognosis judgment and the like.